@xconomy.com 10 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 1 year ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com 1 year ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone